Promising combo for Hard-to-Treat breast cancer hits snag, trial halted
NCT ID NCT01980277
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug (LY2780301) combined with standard chemotherapy (paclitaxel) in people with advanced HER2-negative breast cancer that had spread or couldn't be removed by surgery. The goal was to find the safest dose and see if the combination could shrink tumors. The trial was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Geroges François Leclerd
Dijon, 21079, France
-
Institut Paoli-Calmettes
Marseille, 13008, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?